Glucovance Related Published Studies
Well-designed clinical trials related to Glucovance (Glyburide / Metformin)
Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes. [2006.07]
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. [2005.10]
PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. [2005.09]
Durable efficacy of metformin/glibenclamide combination tablets (Glucovance) during 52 weeks of open-label treatment in type 2 diabetic patients with hyperglycaemia despite previous sulphonylurea monotherapy. [2004.09]
Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. [2004.02.15]
The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study. [2003.10]
Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. [2003.08]
Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. [2003.05]
Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes. [2003.05]
Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus. [2003.02]
Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. [2002.11]
Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. [2002.09]
Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. [2002.08]
Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. [2002.05]
Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. [2002]
Well-designed clinical trials possibly related to Glucovance (Glyburide / Metformin)
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. [2003.07]
Other research related to Glucovance (Glyburide / Metformin)
Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. [2007.11]
Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes. [2006.06.02]
Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus. [2004]
Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. [2003.11]
Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes. [2003.08]
[Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease] [2003.06]
Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. [2002.09]
Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. [2001.02]
Other possibly related research studies
Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. [2007.03]
[Recent oral antidiabetic therapy] [2005.09]
Diabetes mellitus in a domesticated Spanish mustang. [2005.02.15]
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. [2004.03.08]
The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. [2003]
Slow response to loss of glycemic control in type 2 diabetes mellitus. [2003.03]
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. [2004.08]
Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. [2002.03]
Management of type 2 diabetes: update on new pharmacological options. [2000.08]
Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. [2007.10.17]
Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications. [2008.02.21]
Impact of fixed-dose combination drugs on adherence to prescription medications. [2008.05]
Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. [2008.08]
|
